FTC settles Amgen/Horizon challenge
Amgen and Horizon Therapeutics can proceed with their $27.8 billion merger after entering a settlement with the Federal Trade Commission that prevents the new company from bundling Horizon’s rare disease treatments.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10